<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02155712</url>
  </required_header>
  <id_info>
    <org_study_id>74</org_study_id>
    <nct_id>NCT02155712</nct_id>
  </id_info>
  <brief_title>Triathlon Tritanium Knee Outcomes Study</brief_title>
  <official_title>Triathlon Tritanium Knee Outcomes Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stryker Orthopaedics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stryker Orthopaedics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The success of the Triathlon Tritanium Knee will be determined by comparing the rate of
      absence of revision for aseptic loosening of the tibial baseplate at 2 years with the rates
      reported in the literature.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cases are to be enrolled at five to ten centers. The same center may be included in both
      arms. Conversely, a center may choose to participate in only a single arm. The enrollment
      goal is approximately 36 - 72 cases per center for Cohort 1 (cementless) and 15 - 30 cases
      per center for Cohort 2 (cemented) , and will vary dependent upon the number of participating
      centers. Although a goal is presented, there is no maximum limit to the number of cases that
      a center may enroll. In the event that a center far exceeds the enrollment goal, Stryker may
      ask the center to cease enrollment so as not to skew the data. All participating centers will
      comply with the federal regulations regarding patient informed consent and Institutional
      Review Board (IRB) or Ethics Committee (EC) approval. Non-compliance of a study center may
      result in termination of the center's participation in the study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Actual">April 5, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Knees With Cementless Application That Had Successful Primary Total Knee Replacement With the Triathlon Tritanium Total Knee System</measure>
    <time_frame>2 years</time_frame>
    <description>Success is defined as freedom from Triathlon Tritanium Tibial Baseplate revision for aseptic loosening.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implant Survivorship (Baseplate and Patella)</measure>
    <time_frame>10 years</time_frame>
    <description>This outcome measure will be entered at the 10-year time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare 2011 Knee Society Score (KSS) Scores Between Both Groups</measure>
    <time_frame>2 years</time_frame>
    <description>The 2011 Knee Society Score System is comprised of 4 distinct sub-scores: Objective, Functional, Satisfaction, and Expectations. The Objective and Functional sub-scores range from a potential minimum score of 0 to a maximum score of 100 points. The Patient Satisfaction sub-score ranges from a potential minimum score of 0 to a maximum score of 40 points. The Subject Expectations sub-score ranges from a potential minimum score of 0 to a maximum score of 15 points. Although the specific scores are not distinguished as &quot;excellent,&quot; &quot;good,&quot; &quot;fair,&quot; or &quot;poor,&quot; a higher value represents a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Oxford Knee Score (OKS) Scores Between Both Groups</measure>
    <time_frame>2 years</time_frame>
    <description>The OKS questionnaire consists of 12 questions that cover function and pain of the knee. Each question is scored from 0 to 4 (0 being the worst outcome and 4 being the best). The overall score is the sum of all items and can range from 0 to 48, with higher scores corresponding to better outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Short Form-12 (SF-12) Scores Between Both Groups</measure>
    <time_frame>2 years</time_frame>
    <description>The SF-12 Health Survey is a 12-item patient completed questionnaire to measure general health and well-being. It includes a physical and mental status component score; each ragning from 0-100. Low values represent a poor health state and high values represent a good health state.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">588</enrollment>
  <condition>Arthroplasty, Replacement, Knee</condition>
  <arm_group>
    <arm_group_label>Triathlon Tritanium Knee</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cases are enrolled in the Cohort 1 (cementless) until a total of 356 cases receive the Triathlon Tritanium Tibial Baseplate, Triathlon Tritanium Patella, Triathlon CR or PS Beaded Femur with PA and the Triathlon Tibial Insert. All components in this cohort must used in a cementless application.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triathlon Knee</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enrollment in Cohort 2 (cemented) will begin upon completion of enrollment into the Cohort 1 (cementless), and will continue until a total of 144 cases receive the Triathlon Tibial Tray, Triathlon Patella, Triathlon CR or PS Femur and Triathlon Tibial Insert. All components in this cohort must be used in a cemented application.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Triathlon Tritanium Knee</intervention_name>
    <description>Cementless</description>
    <arm_group_label>Triathlon Tritanium Knee</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Triathlon Knee</intervention_name>
    <description>Cemented</description>
    <arm_group_label>Triathlon Knee</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient has signed an Institutional Review Board (IRB)/Ethics Committee (EC) approved;
             study specific Informed Patient Consent Form.

          2. Patient is a male or non-pregnant female age 18-75 years at time of study device
             implantation.

          3. Patient has a diagnosis of Non-Inflammatory Degenerative Joint Disease (NIDJD).

          4. Patient is a candidate for primary cementless total knee replacement, including a
             resurfaced patella.

          5. Patient is willing and able to comply with postoperative scheduled clinical and
             radiographic evaluations and rehabilitation.

        Exclusion Criteria:

          1. Patient has a Body Mass Index (BMI) &gt; 40.

          2. Patient has a diagnosis of avascular necrosis or inflammatory arthritis.

          3. Patient has an active or suspected latent infection in or about the affected knee
             joint at time of study device implantation.

          4. Patient has a neuromuscular or neurosensory deficiency, which limits the ability to
             evaluate the safety and efficacy of the device.

          5. Subject is diagnosed with a systemic disease (e.g. Lupus Erythematosus) or a metabolic
             disorder (e.g. Paget's Disease) leading to progressive bone deterioration.

          6. Patient is immunologically suppressed or receiving steroids in excess of normal
             physiological requirements (e.g. &gt; 30 days).

          7. Patient is diagnosed with lumbar radicular pain.

          8. Patient has a known sensitivity to device materials.

          9. Patient is a prisoner.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Petrow, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tucson Orthopaedic Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabio Orozco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rothman Orthopaedic Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Heekin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heekin Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kipling Sharpe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OrthoArizona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcus Barnett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mission Hospital Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Noble, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Masini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Joseph Mercy Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samuel Wellman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald Delanois, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sinai Hospital of Baltimore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Bowen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geisinger Orthopaedic Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OrthoArizona</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tucson Orthopaedic Institute</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heekin Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial Health</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Health System</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rothman Orthopaedic Institute</name>
      <address>
        <city>Egg Harbor Township</city>
        <state>New Jersey</state>
        <zip>08234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Hospital Research Institute</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Orthopaedic Institute</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 2, 2014</study_first_submitted>
  <study_first_submitted_qc>June 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2014</study_first_posted>
  <results_first_submitted>April 4, 2019</results_first_submitted>
  <results_first_submitted_qc>June 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 16, 2019</results_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 30, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT02155712/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Cohort 1: 383 subjects/451 knees enrolled - 72 subjects/78 knees censored = 319 subjects/373 knees followed.Cohort 2: 205 subjects/229 knees enrolled - 75 subjects/82 knees censored = 134 subjects/147 knees followed.8 bilateral cases in Cohort 1 and 4 in Cohort 2 had 1 side censored and 1 side completed.These count in censored and followed counts.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1 Cementless</title>
          <description>Cases are enrolled in the Cohort 1 (cementless) until a total of 356 cases receive the Triathlon Tritanium Tibial Baseplate, Triathlon Tritanium Patella, Triathlon CR or PS Beaded Femur with PA and the Triathlon Tibial Insert. All components in this cohort must used in a cementless application.
It should be noted that Cohort 1 over-enrolled by 17 cases for a total of 373 cases.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2 Cemented</title>
          <description>Enrollment in Cohort 2 (cemented) will begin upon completion of enrollment into the Cohort 1 (cementless), and will continue until a total of 144 cases receive the Triathlon Tibial Tray, Triathlon Patella, Triathlon CR or PS Femur and Triathlon Tibial Insert. All components in this cohort must be used in a cemented application.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Primary Objective</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="319"/>
                <participants group_id="P2" count="0">Cohort 2 isn't included in primary obj analysis</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="259"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No 2-Year Forms but not Terminated</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Revision/Removal of Tibial Baseplate</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Secondary Objectives</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="319"/>
                <participants group_id="P2" count="134">This period will be updated when posting secondary objective results.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="319"/>
                <participants group_id="P2" count="134"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Includes all participants who received the Triathlon Knee System and were not censored from analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1 Cementless</title>
          <description>Cases are enrolled in the Cohort 1 (cementless) until a total of 356 cases receive the Triathlon Tritanium Tibial Baseplate, Triathlon Tritanium Patella, Triathlon CR or PS Beaded Femur with PA and the Triathlon Tibial Insert. All components in this cohort must used in a cementless application.
Triathlon Tritanium Knee: Cementless</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2 Cemented</title>
          <description>Enrollment in Cohort 2 (cemented) will begin upon completion of enrollment into the Cohort 1 (cementless), and will continue until a total of 144 cases receive the Triathlon Tibial Tray, Triathlon Patella, Triathlon CR or PS Femur and Triathlon Tibial Insert. All components in this cohort must be used in a cemented application.
Triathlon Knee: Cemented</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="319"/>
            <count group_id="B2" value="134"/>
            <count group_id="B3" value="453"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>Knees</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="373"/>
            <count group_id="B2" value="147"/>
            <count group_id="B3" value="520"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.46" spread="7.19"/>
                    <measurement group_id="B2" value="63.07" spread="7.71"/>
                    <measurement group_id="B3" value="62.64" spread="7.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="212"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="299"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="426"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="319"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Knees With Cementless Application That Had Successful Primary Total Knee Replacement With the Triathlon Tritanium Total Knee System</title>
        <description>Success is defined as freedom from Triathlon Tritanium Tibial Baseplate revision for aseptic loosening.</description>
        <time_frame>2 years</time_frame>
        <population>The primary objective analysis only includes cementless, Cohort 1 participants. All Cohort 2 participants received cemented primary total knee replacements and are not included in the primary objective analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 Cementless</title>
            <description>Cases are enrolled in the Cohort 1 (cementless) until a total of 356 cases receive the Triathlon Tritanium Tibial Baseplate, Triathlon Tritanium Patella, Triathlon CR or PS Beaded Femur with PA and the Triathlon Tibial Insert. All components in this cohort must used in a cementless application.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 Cemented</title>
            <description>Enrollment in Cohort 2 (cemented) will begin upon completion of enrollment into the Cohort 1 (cementless), and will continue until a total of 144 cases receive the Triathlon Tibial Tray, Triathlon Patella, Triathlon CR or PS Femur and Triathlon Tibial Insert. All components in this cohort must be used in a cemented application.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Knees With Cementless Application That Had Successful Primary Total Knee Replacement With the Triathlon Tritanium Total Knee System</title>
          <description>Success is defined as freedom from Triathlon Tritanium Tibial Baseplate revision for aseptic loosening.</description>
          <population>The primary objective analysis only includes cementless, Cohort 1 participants. All Cohort 2 participants received cemented primary total knee replacements and are not included in the primary objective analysis.</population>
          <units>Successful Knees</units>
          <param>Number</param>
          <units_analyzed>Knees</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Knees</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Implant Survivorship (Baseplate and Patella)</title>
        <description>This outcome measure will be entered at the 10-year time point.</description>
        <time_frame>10 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare 2011 Knee Society Score (KSS) Scores Between Both Groups</title>
        <description>The 2011 Knee Society Score System is comprised of 4 distinct sub-scores: Objective, Functional, Satisfaction, and Expectations. The Objective and Functional sub-scores range from a potential minimum score of 0 to a maximum score of 100 points. The Patient Satisfaction sub-score ranges from a potential minimum score of 0 to a maximum score of 40 points. The Subject Expectations sub-score ranges from a potential minimum score of 0 to a maximum score of 15 points. Although the specific scores are not distinguished as &quot;excellent,&quot; &quot;good,&quot; &quot;fair,&quot; or &quot;poor,&quot; a higher value represents a better outcome.</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Oxford Knee Score (OKS) Scores Between Both Groups</title>
        <description>The OKS questionnaire consists of 12 questions that cover function and pain of the knee. Each question is scored from 0 to 4 (0 being the worst outcome and 4 being the best). The overall score is the sum of all items and can range from 0 to 48, with higher scores corresponding to better outcomes.</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Short Form-12 (SF-12) Scores Between Both Groups</title>
        <description>The SF-12 Health Survey is a 12-item patient completed questionnaire to measure general health and well-being. It includes a physical and mental status component score; each ragning from 0-100. Low values represent a poor health state and high values represent a good health state.</description>
        <time_frame>2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data is provided from enrollment through the 2-year postoperative interval.</time_frame>
      <desc>All operative site events occurring at any time, as well as all serious adverse events (SAEs) occurring in the perioperative period (intraoperative to hospital discharge), are collected. Specific Adverse Event terms are not used for all Adverse Events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1 Cementless</title>
          <description>Cases are enrolled in the Cohort 1 (cementless) until a total of 356 cases receive the Triathlon Tritanium Tibial Baseplate, Triathlon Tritanium Patella, Triathlon CR or PS Beaded Femur with PA and the Triathlon Tibial Insert. All components in this cohort must used in a cementless application.
Triathlon Tritanium Knee: Cementless</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2 Cemented</title>
          <description>Enrollment in Cohort 2 (cemented) will begin upon completion of enrollment into the Cohort 1 (cementless), and will continue until a total of 144 cases receive the Triathlon Tibial Tray, Triathlon Patella, Triathlon CR or PS Femur and Triathlon Tibial Insert. All components in this cohort must be used in a cemented application.
Triathlon Knee: Cemented</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders - Systemic</sub_title>
                <description>Low hemoglobin</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders - Systemic</sub_title>
                <description>Cohort 1: Arrhythmia; Aortic valve disease Cohort 2: Paroxysmal Atrial Fibrillation; ST segment changes, positive cardiac enzymes, left pneumothorax</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders - Systemic</sub_title>
                <description>Nausea; Odynophagia; Pancreatic Adenocarcinoma</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="319"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Loosening Femoral Component</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications - Wound Related</sub_title>
                <description>Patient bumped into car door and incision on operative knee opened up</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Injury, poisoning and procedural complications - Systemic</sub_title>
                <description>Anesthesia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Deep Joint Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthrofibrosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="319"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Excessive Knee Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders - Wound Related</sub_title>
                <description>Cohort 1: Patient had a fall at home - causing wound to open and significant bleeding.
Cohort 2: Wound hematoma</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Tibial Component Loosening</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Loosening Patellar Component</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders - Operative Site Other</sub_title>
                <description>Severe right knee stiffness</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders - Systemic</sub_title>
                <description>Toxic metabolic encephalopathy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Peroneal Nerve Palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders - Systemic</sub_title>
                <description>Urinary retention; Acute kidney injury; Low urine output/dehydration</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="319"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Soft Tissue Trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Wound Related</sub_title>
                <description>Cellulitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="319"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders - operative site</sub_title>
                <description>Events include arthrofibrosis, excessive knee pain, patellar fracture, soft tissue trauma, superficial wound infection, wound hematoma, tendinitis, IT band syndrome, effusion, swelling, bursitis, neuroma, lesion, bruising, incision dehiscence, etc.</description>
                <counts group_id="E1" events="66" subjects_affected="51" subjects_at_risk="319"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Each investigator shall have privileges for their own center's results at the completion of the study.These manuscripts &amp; abstracts will be delayed until after the multi-center publication is submitted.All publications shall be submitted to the sponsor for review at least 60 days prior to the submission for publication.The sponsor shall not edit or otherwise influence the publications other than to ensure that confidential information is not disclosed and that the data is accurately represented.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ellen Axelson, Director, Clinical Operations</name_or_title>
      <organization>Stryker Orthopaedics</organization>
      <phone>201-831-5401</phone>
      <email>ellen.axelson@stryker.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

